Icosavax Reports Second Quarter 2022 Financial Results and

– Announced positive topline interim Phase 1/1b results for VLP vaccine candidate IVX-121 against respiratory syncytial virus (RSV) - – Icosavax plans...

Related Keywords

United States ,Jessica Yingling ,Laurence Watts ,Adam Simpson ,Institute For Protein Design ,Little Dog Communications Inc ,Nasdaq ,Exchange Commission ,Icosavax Inc ,University Of Washington ,Gilmartin Group ,Chief Executive Officer ,Receptor Binding Domain ,Protein Design ,Private Securities Litigation Reform Act ,Nasdaq Icvx ,Icosavax ,Nc ,Nitgens ,Infectious Diseases ,Metapneumovirus ,Respiratory Syncytial Virus ,Vaccine ,Ars Cov 2 ,Mpv ,Rsv ,Help ,